In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Chronic if current blockade prevents heart rate lowering during acute vagal stimulation

Session Poster session 2

Speaker Alina Scridon

Event : EHRA 2019

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Arrhythmias
  • Session type : Poster Session

Authors : A Scridon (Tirgu Mures,RO), VB Halatiu (Tirgu Mures,RO), AI Balan (Tirgu Mures,RO), DA Cozac (Tirgu Mures,RO), M Perian (Tirgu Mures,RO), RC Serban (Tirgu Mures,RO)

Authors:
A Scridon1 , VB Halatiu2 , AI Balan2 , DA Cozac2 , M Perian2 , RC Serban3 , 1University of Medicine and Pharmacy, Center for Advanced Medical and Pharmaceutical Research - Tirgu Mures - Romania , 2University of Medicine and Pharmacy - Tirgu Mures - Romania , 3University of Medicine and Pharmacy, Emergency Institute for CV Diseases and Transplantation - Tirgu Mures - Romania ,

On behalf: NA

Citation:

Background: Ivabradine, an If current blocker, has shown promising results in the treatment of patients with sinus tachycardia-mediated vasovagal syncope (VVS). However, the effects of ivabradine in the setting of VVS without prior sinus tachycardia remain unknown.

Purpose: We aimed to assess the effects of chronic ivabradine administration on the heart rate and blood pressure of in vivo rats and on in vitro sinus node discharge rate, both during acute parasympathetic stimulation.

Methods: Thirteen adult male Wistar rats were randomized into two groups: control (C; n=6) and treated with ivabradine (IVA; 10 mg/kg/day, for three consecutive weeks; n=7). The right vagus nerve was isolated in all rats. The intact vagus nerve was stimulated electrically at a frequency of 2, 5, 10, and 20 Hz (15 s each) with 5-min intervals between stimulations (pulse duration 0.5 ms; 20 V). The nerve was then sectioned and the distal end was stimulated using the same protocol. The heart rate and the systolic blood pressure were measured non-invasively at baseline and during each stimulation. The right atrium was then removed, placed in the Steiert organ bath, and the discharge rate of the sinus node was assessed in vitro at baseline and after applying carbamylcholine in progressively higher concentrations (10-9 to 10-6 mol/L).

Results: As expected, the two groups displayed similar baseline systolic blood pressure (p=0.95), but IVA rats presented significantly lower heart rates compared to the C rats (p=0.02). A significant, progressive decrease in systolic blood pressure was recorded during electrical stimulation of both the intact and the sectioned vagus nerves, in both the C and the IVA rats (all p<0.001). In the C rats, a significant, progressive decrease in heart rate was also recorded during electrical stimulation of both the intact and the sectioned vagus nerves (both p<0.0001). In the IVA rats, however, electrical stimulation of the intact or the sectioned vagus nerves had no effect on the heart rate (both p >0.05). A significant, progressive decrease in sinus node discharge rate was also observed in vitro, after applying progressively higher carbamylcholine concentrations, in both the C and the IVA rats (both p<0.001).

Conclusion: In rats, chronic If current blockade prevented the heart rate lowering effect of acute in vivo vagus nerve stimulation, without affecting the blood pressure response. Meanwhile, ivabradine administration had no effect on sinus node discharge rate lowering in response to direct acetylcholine receptors stimulation. These results suggest that the beneficial effects of ivabradine reported in patients with tachycardia-mediated VVS may also extend to patients with vagal hypersensitivity and excessive cardioinhibitory responses. Our data also suggest that this ‘protective’ ivabradine effect is likely to be related to an effect of ivabradine on ganglionic transmission and/or on postganglionic cholinergic fibers.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are